Jing-Ping Liou, PhD - Publications

1990-1994 College of Pharmacy Taipei Medical University 
 1994-2000 College of Pharmacy National Taiwan University, London, Taipei City, Taiwan 
 2000-2004 National Health Research Institutes, Taiwan, Taiwan 
 2004- College of Pharmacy Taipei Medical University 
Medicinal Chemistry, Drug Discovery, Translational Medicine, Drug Design, Drug Development

81 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Huang HL, Liu YM, Sung TY, Huang TC, Cheng YW, Liou JP, Pan SL. TIMP3 expression associates with prognosis in colorectal cancer and its novel arylsulfonamide inducer, MPT0B390, inhibits tumor growth, metastasis and angiogenesis. Theranostics. 9: 6676-6689. PMID 31588243 DOI: 10.7150/thno.34020  0.56
2019 Nepali K, Lin MH, Chao MW, Peng SJ, Hsu KC, Eight Lin T, Chen MC, Lai MJ, Pan SL, Liou JP. Amide-tethered quinoline-resorcinol conjugates as a new class of HSP90 inhibitors suppressing the growth of prostate cancer cells. Bioorganic Chemistry. 91: 103119. PMID 31349117 DOI: 10.1016/j.bioorg.2019.103119  0.56
2019 Chao MW, Chang LH, Tu HJ, Chang CD, Lai MJ, Chen YY, Liou JP, Teng CM, Pan SL. Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status. Clinical Epigenetics. 11: 85. PMID 31142371 DOI: 10.1186/s13148-019-0681-6  0.56
2019 Huang FI, Wu YW, Sung TY, Liou JP, Lin MH, Pan SL, Yang CR. MPT0G413, A Novel HDAC6-Selective Inhibitor, and Bortezomib Synergistically Exert Anti-tumor Activity in Multiple Myeloma Cells. Frontiers in Oncology. 9: 249. PMID 31024851 DOI: 10.3389/fonc.2019.00249  0.56
2018 Tu HJ, Lin YJ, Chao MW, Sung TY, Wu YW, Chen YY, Lin MH, Liou JP, Pan SL, Yang CR. The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells. Clinical Epigenetics. 10: 162. PMID 30594243 DOI: 10.1186/s13148-018-0595-8  0.56
2018 Nepali K, Lee HY, Liou JP. Nitro Group Containing Drugs. Journal of Medicinal Chemistry. PMID 30295477 DOI: 10.1021/acs.jmedchem.8b00147  0.52
2018 Wu CC, Lee PT, Kao TJ, Chou SY, Su RY, Lee YC, Yeh SH, Liou JP, Hsu TI, Su TP, Chuang CK, Chang WC, Chuang JY. Upregulation of Znf179 acetylation by SAHA protects cells against oxidative stress. Redox Biology. 19: 74-80. PMID 30121389 DOI: 10.1016/j.redox.2018.08.001  0.48
2018 Lee HY, Fan SJ, Huang FI, Chao HY, Hsu KC, Lin TE, Yeh TK, Lai MJ, Li YH, Huang HL, Yang CR, Liou JP. 5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes. Journal of Medicinal Chemistry. PMID 30028616 DOI: 10.1021/acs.jmedchem.8b00151  0.56
2018 Nepali K, Kumar S, Huang HL, Kuo FC, Lee CH, Kuo CC, Yeh TK, Li YH, Chang JY, Liou JP, Lee HY. Correction: 2-Aroylquinoline-5,8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (HSP90) inhibition. Organic & Biomolecular Chemistry. PMID 29904758 DOI: 10.1039/c8ob90080a  0.56
2018 Fan SJ, Huang FI, Liou JP, Yang CR. The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model. Cell Death & Disease. 9: 655. PMID 29844403 DOI: 10.1038/s41419-018-0688-5  0.36
2018 Wu YW, Hsu KC, Lee HY, Huang TC, Lin TE, Chen YL, Sung TY, Liou JP, Hwang-Verslues WW, Pan SL, HuangFu WC. A Novel Dual HDAC6 and Tubulin Inhibitor, MPT0B451, Displays Anti-tumor Ability in Human Cancer Cellsand. Frontiers in Pharmacology. 9: 205. PMID 29593536 DOI: 10.3389/fphar.2018.00205  0.56
2018 Tsai IT, Kuo CC, Liou JP, Chang JY. Novel microtubule inhibitor MPT0B098 inhibits hypoxia-induced epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma. Journal of Biomedical Science. 25: 28. PMID 29592811 DOI: 10.1186/s12929-018-0432-6  0.44
2018 Ojha R, Huang HL, HuangFu WC, Wu YW, Nepali K, Lai MJ, Su CJ, Sung TY, Chen YL, Pan SL, Liou JP. 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC. European Journal of Medicinal Chemistry. 150: 667-677. PMID 29567459 DOI: 10.1016/j.ejmech.2018.03.006  0.56
2017 Wu TY, Cho TY, Lu CK, Liou JP, Chen MC. Identification of 7-(4'-Cyanophenyl)indoline-1-benzenesulfonamide as a mitotic inhibitor to induce apoptotic cell death and inhibit autophagy in human colorectal cancer cells. Scientific Reports. 7: 12406. PMID 28963527 DOI: 10.1038/s41598-017-12795-5  0.52
2017 Chang KY, Hsu TI, Hsu CC, Tsai SY, Liu JJ, Chou SW, Liu MS, Liou JP, Ko CY, Chen KY, Hung JJ, Chang WC, Chuang CK, Kao TJ, Chuang JY. Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O(6)-methylguanine-DNA methyltransferase. Redox Biology. 13: 655-664. PMID 28822335 DOI: 10.1016/j.redox.2017.08.005  0.48
2017 Kumar S, Lee HY, Liou JP. Total Synthesis of Two Glycosylated Stilbenes, Oxyresveratrol 2-O-β-d-Glucopyranoside and 2,3,5,4'-Tetrahydroxystilbene 2-O-β-d-Glucopyranoside. Journal of Natural Products. PMID 28429937 DOI: 10.1021/acs.jnatprod.6b00861  0.52
2017 Mehndiratta S, Wang RS, Huang HL, Su CJ, Hsu CM, Wu YW, Pan SL, Liou JP. 4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo. European Journal of Medicinal Chemistry. 134: 13-23. PMID 28395150 DOI: 10.1016/j.ejmech.2017.03.079  0.56
2017 HuangFu WC, Chao MW, Cheng CC, Wei YC, Wu YW, Liou JP, Hsiao G, Lee YC, Yang CR. Anti-leukemia effects of the novel synthetic 1-benzylindole derivative 21-900 in vitro and in vivo. Scientific Reports. 7: 42291. PMID 28181578 DOI: 10.1038/srep42291  0.56
2017 Tien YE, Li CJ, Liou JP, Chang JY, Huang JD. Pharmacokinetics and protein binding of MPT0B292. Biopharmaceutics & Drug Disposition. PMID 28144964 DOI: 10.1002/bdd.2067  0.4
2016 Nepali K, Lee HY, Lai MJ, Ojha R, Wu TY, Wu GX, Chen MC, Liou JP. Ring-opened tetrahydro-γ-carbolines display cytotoxicity and selectivity with histone deacetylase isoforms. European Journal of Medicinal Chemistry. 127: 115-127. PMID 28038324 DOI: 10.1016/j.ejmech.2016.12.039  0.56
2016 Lee HY, Lee JF, Kumar S, Wu YW, HuangFu WC, Lai MJ, Li YH, Huang HL, Kuo FC, Hsiao CJ, Cheng CC, Yang CR, Liou JP. 3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity. European Journal of Medicinal Chemistry. 125: 1268-1278. PMID 27886544 DOI: 10.1016/j.ejmech.2016.11.033  0.56
2016 Hsu CC, Chang WC, Hsu TI, Liu JJ, Yeh SH, Wang JY, Liou JP, Ko CY, Chang KY, Chuang JY. Suberoylanilide hydroxamic acid represses glioma stem-like cells. Journal of Biomedical Science. 23: 81. PMID 27863490 DOI: 10.1186/s12929-016-0296-6  0.48
2016 Peng HY, Cheng YC, Hsu YM, Wu GH, Kuo CC, Liou JP, Chang JY, Jin SC, Shiah SG. MPT0B098, a Microtubule Inhibitor, Suppresses JAK2/STAT3 Signaling Pathway through Modulation of SOCS3 Stability in Oral Squamous Cell Carcinoma. Plos One. 11: e0158440. PMID 27367272 DOI: 10.1371/journal.pone.0158440  0.44
2015 Chen MC, Huang HH, Lai CY, Lin YJ, Liou JP, Lai MJ, Li YH, Teng CM, Yang CR. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma. Oncotarget. PMID 26587975 DOI: 10.18632/oncotarget.6352  0.52
2015 Lai MJ, Lee HY, Chuang HY, Chang LH, Tsai AC, Chen MC, Huang HL, Wu YW, Teng CM, Pan SL, Liu YM, Mehndiratta S, Liou JP. N-Sulfonyl-aminobiaryls as Antitubulin Agents and Inhibitors of Signal Transducer and Activator of Transcription 3 (STAT3) Signaling. Journal of Medicinal Chemistry. PMID 26241032 DOI: 10.1021/acs.jmedchem.5b00659  0.44
2015 Lee HY, Chang CY, Lai MJ, Chuang HY, Kuo CC, Chang CY, Chang JY, Liou JP. Antimitotic and antivascular activity of heteroaroyl-2-hydroxy-3,4,5-trimethoxybenzenes. Bioorganic & Medicinal Chemistry. 23: 4230-6. PMID 26160020 DOI: 10.1016/j.bmc.2015.06.043  0.52
2015 Chao MW, Lai MJ, Liou JP, Chang YL, Wang JC, Pan SL, Teng CM. The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo. Journal of Hematology & Oncology. 8: 82. PMID 26156322 DOI: 10.1186/s13045-015-0176-7  0.56
2015 Huang YC, Huang FI, Mehndiratta S, Lai SC, Liou JP, Yang CR. Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis. Oncotarget. PMID 26087180  0.44
2015 Pai HC, Kumar S, Shen CC, Liou JP, Pan SL, Teng CM. MT-4 suppresses resistant ovarian cancer growth through targeting tubulin and HSP27. Plos One. 10: e0123819. PMID 25874627 DOI: 10.1371/journal.pone.0123819  0.44
2015 Huang HL, Peng CY, Lai MJ, Chen CH, Lee HY, Wang JC, Liou JP, Pan SL, Teng CM. Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo. Oncotarget. 6: 4976-91. PMID 25669976  0.44
2015 Liu YM, Lee HY, Chen CH, Lee CH, Wang LT, Pan SL, Lai MJ, Yeh TK, Liou JP. 1-Arylsulfonyl-5-(N-hydroxyacrylamide)tetrahydroquinolines as potent histone deacetylase inhibitors suppressing the growth of prostate cancer cells. European Journal of Medicinal Chemistry. 89: 320-30. PMID 25462248 DOI: 10.1016/j.ejmech.2014.10.052  0.44
2014 Chung CC, Kao YH, Liou JP, Chen YJ. Curcumin Suppress Cardiac Fibroblasts Activities by Regulating Proliferation, Migration, and the Extracellular Matrix. Zhonghua Minguo Xin Zang Xue Hui Za Zhi = Acta Cardiologica Sinica. 30: 474-82. PMID 27122821  0.32
2014 Hou P, Kuo CY, Cheng CT, Liou JP, Ann DK, Chen Q. Intermediary metabolite precursor dimethyl-2-ketoglutarate stabilizes hypoxia-inducible factor-1α by inhibiting prolyl-4-hydroxylase PHD2. Plos One. 9: e113865. PMID 25420025 DOI: 10.1371/journal.pone.0113865  0.44
2014 Lee HY, Wang LT, Li YH, Pan SL, Chen YL, Teng CM, Liou JP. Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases. Organic & Biomolecular Chemistry. 12: 8966-76. PMID 25277250 DOI: 10.1039/c4ob00542b  0.44
2014 Wang CY, Liou JP, Tsai AC, Lai MJ, Liu YM, Lee HY, Wang JC, Pan SL, Teng CM. A novel action mechanism for MPT0G013, a derivative of arylsulfonamide, inhibits tumor angiogenesis through up-regulation of TIMP3 expression. Oncotarget. 5: 9838-50. PMID 25226613  0.44
2014 Chung CC, Hsu RC, Kao YH, Liou JP, Lu YY, Chen YJ. Androgen attenuates cardiac fibroblasts activations through modulations of transforming growth factor-β and angiotensin II signaling. International Journal of Cardiology. 176: 386-93. PMID 25125004 DOI: 10.1016/j.ijcard.2014.07.077  0.44
2014 Mehndiratta S, Hsieh YL, Liu YM, Wang AW, Lee HY, Liang LY, Kumar S, Teng CM, Yang CR, Liou JP. Indole-3-ethylsulfamoylphenylacrylamides: potent histone deacetylase inhibitors with anti-inflammatory activity. European Journal of Medicinal Chemistry. 85: 468-79. PMID 25113875 DOI: 10.1016/j.ejmech.2014.08.020  0.44
2014 Mehndiratta S, Chiang YF, Lai MJ, Lee HY, Chen MC, Kuo CC, Chang CY, Chang JY, Liou JP. Concise syntheses of 7-anilino-indoline-N-benzenesulfonamides as antimitotic and vascular disrupting agents. Bioorganic & Medicinal Chemistry. 22: 4917-23. PMID 25059503 DOI: 10.1016/j.bmc.2014.06.042  0.44
2014 Yang CR, Shih KS, Liou JP, Wu YW, Hsieh IN, Lee HY, Lin TC, Wang JH. Denbinobin upregulates miR-146a expression and attenuates IL-1β-induced upregulation of ICAM-1 and VCAM-1 expressions in osteoarthritis fibroblast-like synoviocytes. Journal of Molecular Medicine (Berlin, Germany). PMID 25052989 DOI: 10.1007/s00109-014-1192-8  0.44
2014 Wang LT, Liou JP, Li YH, Liu YM, Pan SL, Teng CM. A novel class I HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/PKCδ and E-cadherin. Oncotarget. 5: 5651-62. PMID 25015091  0.52
2014 Lee HY, Tsai AC, Chen MC, Shen PJ, Cheng YC, Kuo CC, Pan SL, Liu YM, Liu JF, Yeh TK, Wang JC, Chang CY, Chang JY, Liou JP. Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells. Journal of Medicinal Chemistry. 57: 4009-22. PMID 24766560 DOI: 10.1021/jm401899x  0.44
2014 Chang CY, Chuang HY, Lee HY, Yeh TK, Kuo CC, Chang CY, Chang JY, Liou JP. Antimitotic and vascular disrupting agents: 2-hydroxy-3,4,5-trimethoxybenzophenones. European Journal of Medicinal Chemistry. 77: 306-14. PMID 24657567 DOI: 10.1016/j.ejmech.2014.02.061  0.44
2014 Chen CH, Chen MC, Wang JC, Tsai AC, Chen CS, Liou JP, Pan SL, Teng CM. Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1274-87. PMID 24520095 DOI: 10.1158/1078-0432.CCR-12-3909  0.44
2014 Liu YM, Chen HL, Lee HY, Liou JP. Tubulin inhibitors: a patent review. Expert Opinion On Therapeutic Patents. 24: 69-88. PMID 24313741 DOI: 10.1517/13543776.2014.859247  0.52
2014 Tsai AC, Pai HC, Wang CY, Liou JP, Teng CM, Wang JC, Pan SL. In vitro and in vivo anti-tumour effects of MPT0B014, a novel derivative aroylquinoline, and in combination with erlotinib in human non-small-cell lung cancer cells. British Journal of Pharmacology. 171: 122-33. PMID 24116948 DOI: 10.1111/bph.12427  0.44
2013 Lee HY, Pan SL, Su MC, Liu YM, Kuo CC, Chang YT, Wu JS, Nien CY, Mehndiratta S, Chang CY, Wu SY, Lai MJ, Chang JY, Liou JP. Furanylazaindoles: potent anticancer agents in vitro and in vivo. Journal of Medicinal Chemistry. 56: 8008-18. PMID 24106982 DOI: 10.1021/jm4011115  0.44
2013 Lee WH, Liu HE, Chang JY, Liou JP, Huang HM. MPT0B169, a new tubulin inhibitor, inhibits cell growth and induces G2/M arrest in nonresistant and paclitaxel-resistant cancer cells. Pharmacology. 92: 90-8. PMID 23949011 DOI: 10.1159/000351852  0.4
2013 Kao YH, Liou JP, Chung CC, Lien GS, Kuo CC, Chen SA, Chen YJ. Histone deacetylase inhibition improved cardiac functions with direct antifibrotic activity in heart failure. International Journal of Cardiology. 168: 4178-83. PMID 23931972 DOI: 10.1016/j.ijcard.2013.07.111  0.44
2013 Lee HY, Yang CR, Lai MJ, Huang HL, Hsieh YL, Liu YM, Yeh TK, Li YH, Mehndiratta S, Teng CM, Liou JP. 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines histone deacetylase inhibitors are potent cytokine release suppressors. Chembiochem : a European Journal of Chemical Biology. 14: 1248-54. PMID 23788254 DOI: 10.1002/cbic.201300201  0.44
2013 Cheng YC, Liou JP, Kuo CC, Lai WY, Shih KH, Chang CY, Pan WY, Tseng JT, Chang JY. MPT0B098, a novel microtubule inhibitor that destabilizes the hypoxia-inducible factor-1α mRNA through decreasing nuclear-cytoplasmic translocation of RNA-binding protein HuR. Molecular Cancer Therapeutics. 12: 1202-12. PMID 23619299 DOI: 10.1158/1535-7163.MCT-12-0778  0.44
2013 Chiang NJ, Lin CI, Liou JP, Kuo CC, Chang CY, Chen LT, Chang JY. A novel synthetic microtubule inhibitor, MPT0B214 exhibits antitumor activity in human tumor cells through mitochondria-dependent intrinsic pathway. Plos One. 8: e58953. PMID 23554962 DOI: 10.1371/journal.pone.0058953  0.44
2013 Wang CL, Lee O, Huang CF, Li EI, Teng CM, Pan SL, Lian JF, Chang FS, Liou JP, Wang HP. Azatyrosinamides: novel RAS-related anticancer agents. Anticancer Research. 33: 425-32. PMID 23393333  0.52
2012 Lee HY, Lee LW, Nien CY, Kuo CC, Lin PY, Chang CY, Chang JY, Liou JP. Application of Suzuki arylation, Sonogashira ethynylation and Rosenmund-von Braun cyanation in the exploration of substitution effects on the anticancer activity of 2-aroylquinolines. Organic & Biomolecular Chemistry. 10: 9593-600. PMID 23132325 DOI: 10.1039/c2ob26614h  0.52
2012 Huang HL, Huang HL, Lee HY, Tsai AC, Peng CY, Lai MJ, Wang JC, Pan SL, Teng CM, Liou JP. Anticancer activity of MPT0E028, a novel potent histone deacetylase inhibitor, in human colorectal cancer HCT116 cells in vitro and in vivo. Plos One. 7: e43645. PMID 22928010 DOI: 10.1371/journal.pone.0043645  0.44
2012 Lai MJ, Huang HL, Pan SL, Liu YM, Peng CY, Lee HY, Yeh TK, Huang PH, Teng CM, Chen CS, Chuang HY, Liou JP. Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo. Journal of Medicinal Chemistry. 55: 3777-91. PMID 22439863 DOI: 10.1021/jm300197a  0.56
2012 Wang JH, Shih KS, Liou JP, Wu YW, Chang AS, Wang KL, Tsai CL, Yang CR. Anti-arthritic effects of magnolol in human interleukin 1β-stimulated fibroblast-like synoviocytes and in a rat arthritis model. Plos One. 7: e31368. PMID 22359588 DOI: 10.1371/journal.pone.0031368  0.36
2011 Lee HY, Chang JY, Nien CY, Kuo CC, Shih KH, Wu CH, Chang CY, Lai WY, Liou JP. 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. Part 2. The impact of bridging groups at position C-2. Journal of Medicinal Chemistry. 54: 8517-25. PMID 22060033 DOI: 10.1021/jm201031f  0.44
2011 Lai MJ, Chang JY, Lee HY, Kuo CC, Lin MH, Hsieh HP, Chang CY, Wu JS, Wu SY, Shey KS, Liou JP. Synthesis and biological evaluation of 1-(4'-Indolyl and 6'-Quinolinyl) indoles as a new class of potent anticancer agents. European Journal of Medicinal Chemistry. 46: 3623-9. PMID 21641700 DOI: 10.1016/j.ejmech.2011.04.065  0.44
2011 Tung YS, Coumar MS, Wu YS, Shiao HY, Chang JY, Liou JP, Shukla P, Chang CW, Chang CY, Kuo CC, Yeh TK, Lin CY, Wu JS, Wu SY, Liao CC, et al. Scaffold-hopping strategy: synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents. Journal of Medicinal Chemistry. 54: 3076-80. PMID 21434659 DOI: 10.1021/jm101027s  0.44
2011 Lee HY, Chang JY, Chang LY, Lai WY, Lai MJ, Shih KH, Kuo CC, Chang CY, Liou JP. Concise syntheses of N-aryl-5,6,7-trimethoxyindoles as antimitotic and vascular disrupting agents: application of the copper-mediated Ullmann-type arylation. Organic & Biomolecular Chemistry. 9: 3154-7. PMID 21416070 DOI: 10.1039/c0ob01038c  0.44
2011 Hsieh CC, Lee HY, Nien CY, Kuo CC, Chang CY, Chang JY, Liou JP. Synthesis and biological evaluation of 4-aroyl-6,7,8-trimethoxyquinolines as a novel class of anticancer agents. Molecules (Basel, Switzerland). 16: 2274-84. PMID 21383664 DOI: 10.3390/molecules16032274  0.52
2011 Chuang HY, Chang JY, Lai MJ, Kuo CC, Lee HY, Hsieh HP, Chen YJ, Chen LT, Pan WY, Liou JP. 2-amino-3,4,5-trimethoxybenzophenones as potent tubulin polymerization inhibitors. Chemmedchem. 6: 450-6. PMID 21360819 DOI: 10.1002/cmdc.201000479  0.44
2010 Chen CP, Hu CB, Yeh KC, Song JS, Yeh TK, Tung FF, Hwang LL, Tseng HY, Huang YC, Shy HS, Hsieh SH, Shen CC, Wang HS, Hsieh HP, Liou JP, et al. Antiangiogenic activities and cisplatin-combined antitumor activities of BPR0L075. Anticancer Research. 30: 2813-22. PMID 20683017  0.4
2010 Nien CY, Chen YC, Kuo CC, Hsieh HP, Chang CY, Wu JS, Wu SY, Liou JP, Chang JY. 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. Journal of Medicinal Chemistry. 53: 2309-13. PMID 20148562 DOI: 10.1021/jm900685y  0.44
2009 Wu YS, Coumar MS, Chang JY, Sun HY, Kuo FM, Kuo CC, Chen YJ, Chang CY, Hsiao CL, Liou JP, Chen CP, Yao HT, Chiang YK, Tan UK, Chen CT, et al. Synthesis and evaluation of 3-aroylindoles as anticancer agents: metabolite approach. Journal of Medicinal Chemistry. 52: 4941-5. PMID 19586033 DOI: 10.1021/jm900060s  0.44
2009 Lai MJ, Kuo CC, Yeh TK, Hsieh HP, Chen LT, Pan WY, Hsu KY, Chang JY, Liou JP. Synthesis and structure-activity relationships of 1-benzyl-4,5,6-trimethoxyindoles as a novel class of potent antimitotic agents. Chemmedchem. 4: 588-93. PMID 19266513 DOI: 10.1002/cmdc.200800405  0.44
2008 Reddy GR, Kuo CC, Tan UK, Coumar MS, Chang CY, Chiang YK, Lai MJ, Yeh JY, Wu SY, Chang JY, Liou JP, Hsieh HP. Synthesis and structure-activity relationships of 2-amino-1-aroylnaphthalene and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents. Journal of Medicinal Chemistry. 51: 8163-7. PMID 19053773 DOI: 10.1021/jm8008635  0.44
2008 Liou JP, Wu ZY, Kuo CC, Chang CY, Lu PY, Chen CM, Hsieh HP, Chang JY. Discovery of 4-amino and 4-hydroxy-1-aroylindoles as potent tubulin polymerization inhibitors. Journal of Medicinal Chemistry. 51: 4351-5. PMID 18588280 DOI: 10.1021/jm800150d  0.44
2007 Liou JP, Wu CY, Hsieh HP, Chang CY, Chen CM, Kuo CC, Chang JY. 4- and 5-aroylindoles as novel classes of potent antitubulin agents. Journal of Medicinal Chemistry. 50: 4548-52. PMID 17685504 DOI: 10.1021/jm070557q  0.44
2007 Lin HL, Yang MH, Wu CW, Chen PM, Yang YP, Chu YR, Kao CL, Ku HH, Lo JF, Liou JP, Chi CW, Chiou SH. 2-Methoxyestradiol attenuates phosphatidylinositol 3-kinase/Akt pathway-mediated metastasis of gastric cancer. International Journal of Cancer. 121: 2547-55. PMID 17680560 DOI: 10.1002/ijc.22963  0.44
2007 Liou JP, Hsu KS, Kuo CC, Chang CY, Chang JY. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule. The Journal of Pharmacology and Experimental Therapeutics. 323: 398-405. PMID 17660383 DOI: 10.1124/jpet.107.126680  0.44
2006 Chang JY, Hsieh HP, Chang CY, Hsu KS, Chiang YF, Chen CM, Kuo CC, Liou JP. 7-Aroyl-aminoindoline-1-sulfonamides as a novel class of potent antitubulin agents. Journal of Medicinal Chemistry. 49: 6656-9. PMID 17154496 DOI: 10.1021/jm061076u  0.44
2006 Chang JY, Yang MF, Chang CY, Chen CM, Kuo CC, Liou JP. 2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. Journal of Medicinal Chemistry. 49: 6412-5. PMID 17034147 DOI: 10.1021/jm060616k  0.44
2006 Liou JP, Mahindroo N, Chang CW, Guo FM, Lee SW, Tan UK, Yeh TK, Kuo CC, Chang YW, Lu PH, Tung YS, Lin KT, Chang JY, Hsieh HP. Structure-activity relationship studies of 3-aroylindoles as potent antimitotic agents. Chemmedchem. 1: 1106-18. PMID 16952120 DOI: 10.1002/cmdc.200600125  0.44
2004 Liou JP, Chang YL, Kuo FM, Chang CW, Tseng HY, Wang CC, Yang YN, Chang JY, Lee SJ, Hsieh HP. Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents Journal of Medicinal Chemistry. 47: 4247-4257. PMID 15293996 DOI: 10.1021/jm049802l  0.44
2004 Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, Chang YL, Chen LT, Chen CT, Chang JY. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Research. 64: 4621-8. PMID 15231674 DOI: 10.1158/0008-5472.CAN-03-3474  0.44
2004 Juang SH, Pan WY, Kuo CC, Liou JP, Hung YM, Chen LT, Hsieh HP, Chang JY. A novel bis-benzylidenecyclopentanone derivative, BPR0Y007, inducing a rapid caspase activation involving upregulation of Fas (CD95/APO-1) and wild-type p53 in human oral epidermoid carcinoma cells Biochemical Pharmacology. 68: 293-303. PMID 15194001 DOI: 10.1016/j.bcp.2004.03.036  0.44
2004 Liou JP, Chang JY, Chang CW, Chang CY, Mahindroo N, Kuo FM, Hsieh HP. Synthesis and structure-activity relationships of 3-aminobenzophenones as antimitotic agents Journal of Medicinal Chemistry. 47: 2897-2905. PMID 15139768 DOI: 10.1021/jm0305974  0.44
2003 Chang JY, Hsieh HP, Pan WY, Liou JP, Bey SJ, Chen LT, Liu JF, Song JS. Dual inhibition of topoisomerase I and tubulin polymerization by BPR0Y007, a novel cytotoxic agent Biochemical Pharmacology. 65: 2009-2019. PMID 12787881 DOI: 10.1016/S0006-2952(03)00197-7  0.44
2003 Hsieh HP, Liou JP, Lin YT, Mahindroo N, Chang JY, Yang YN, Chern SS, Tan UK, Chang CW, Chen TW, Lin CH, Chang YY, Wang CC. Structure-activity and crystallographic analysis of benzophenone derivatives-the potential anticancer agents. Bioorganic & Medicinal Chemistry Letters. 13: 101-5. PMID 12467626 DOI: 10.1016/S0960-894X(02)00850-8  0.44
2002 Liou JP, Chang CW, Song JS, Yang YN, Yeh CF, Tseng HY, Lo YK, Chang YL, Chang CM, Hsieh HP. Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents. Journal of Medicinal Chemistry. 45: 2556-62. PMID 12036364  0.4
Show low-probability matches.